Download PDF
Psychiatr Prax 2007; 34(5): 223-229
DOI: 10.1055/s-2006-940056
Originalarbeit

© Georg Thieme Verlag KG Stuttgart · New York

Dyslipidämie bei langjähriger neuroleptischer Behandlung

Dyslipidemia and SchizophreniaTilman  Wetterling1 , Barbara  Schneider1 , Bernhard  Weber1
  • 1Klinik für Psychiatrie und Psychotherapie, J.-W.-Goethe-Universität, Frankfurt/M.
Further Information

Publication History

Publication Date:
07 December 2006 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Anliegen Unter Atypikabehandlung können Fettstoffwechselstörungen auftreten. Daher wurden die Serumlipidwerte bei Patienten mit chronischer Schizophrenie untersucht. Methode Serumlipidwerte von 177 konsekutiv stationär aufgenommenen schizophrenen Patienten, für die Daten über eine Behandlung von mehr als 5 Jahren vorlagen, wurden ausgewertet. Ergebnisse Die Serumlipidwerte zeigten keine Geschlechtsunterschiede. Ein erheblicher Teil der Patienten wies erhöhte Triglyzeridwerte (35,6 %) und/oder Cholesterinwerte (43,9 %) auf. Der Anteil der Patienten mit erhöhten Cholesterin- bzw. Triglyzeridwerten steigt mit der Behandlungsdauer. Die Triglyzeridkonzentration korrelierte mit dem Bodymass-Index (p < 0,01). Schlussfolgerungen Die Studie weist auf einen Zusammenhang zwischen der Häufigkeit erhöhter Lipidserumwerte und der Therapiedauer hin.

Abstract

Objective There is some evidence that the treatment with new („atypical”) neuroleptics is associated with a higher frequency of hyperlipidemia. Aim In this study the serum lipid levels of patients with chronic schizophrenia were investigated. Methods The serum lipid levels of 177 consecutively admitted schizophrenic patients treated at least 5 years were evaluated. Results No gender differences of lipid concentrations could be detected. A considerable rate of the patients (35.6 %) showed elevated triglycerides (> 150 mg/dl) or elevated cholesterol levels (> 200 mg/dl; 43.9 %). The rate of patients with elevated cholesterol or triglyceride concentrations is associated with the duration of treatment. The comparison of different groups of neuroleptics yielded at best a trend to higher triglyceride levels in the patients treated with dibenzodiazepines compared to those receiving only classical neuroleptics. The triglyceride concentrations correlated with the body mass index (ρ = 0.25, p < 0.01). Conclusions This study revealed evidence for an association of the rate of patients with elevated lipid levels and duration of neuroleptic treatment in schizophrenia patients.

Schlüsselwörter

Schizophrenie - Neuroleptika - Dyslipidämie - Triglyzeride - Cholesterin

Key words

schizophrenia - neuroleptics - dyslipidemia - triglycerides - cholesterol

Literatur

  • 1 Meyer J M, Koro C E. The effects of antipsychotic therapy on serum lipids: a comprehensive review.  Schizophr Res. 2004;  70 1-17
    PubMedGoogle Scholar
  • 2 Wetterling T. Hyperlipidämie - Nebenwirkung von „atypischen” Neuroleptika?.  Fortschr Neurol Psychiatr. 2003;  71 535-540
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Atmaca M, Kuloglu M, Tezcan E, Gecici O, Ustundag B. Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol.  Schizophr Res. 2003;  60 99-100
    PubMedGoogle Scholar
  • 4 Gaulin B D, Markowitz J S, Caley C F, Nesbitt L A, Dufresne R L. Clozapine-associated elevation in serum triglycerides.  Am J Psychiatry. 1999;  156 1270-1272
    PubMedGoogle Scholar
  • 5 Koro C E, Fedder D O, L'Italien G J, Weiss S, Magder L S, Kreyenbuhl J, Revicki D, Buchanan R W. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients.  Arch Gen Psychiatry. 2002;  59 1021-1026
    PubMedGoogle Scholar
  • 6 Wirshing D A, Boyd J A, Meng L R, Ballon J S, Marder S R, Wirshing W C. The effects of novel antipsychotics on glucose and lipid levels.  J Clin Psychiatry. 2002;  63 856-865
    CrossrefPubMedGoogle Scholar
  • 7 Almeras N, Despres J P, Villeneuve J, Demers M F, Roy M A, Cadrin C, Mottard J P, Bouchard R H. Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics.  J Clin Psychiatry. 2004;  65 557-564
    PubMedGoogle Scholar
  • 8 Lambert B L, Chang K Y, Tafesse E, Carson W. Association between antipsychotic treatment and hyperlipidemia among California Medicaid patients with schizophrenia.  J Clin Psychopharmacol. 2005;  25 12-18
    CrossrefPubMedGoogle Scholar
  • 9 Lindenmayer J P, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy J P, Cooper T B, Chakos M, Lieberman J A. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.  Am J Psychiatry. 2003;  160 290-296
    CrossrefPubMedGoogle Scholar
  • 10 McQuade R D, Stock E, Marcus R, Jody D, Gharbia N A, Vanveggel S, Archibald D, Carson W H. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.  J Clin Psychiatry. 2004;  65, Suppl 18 47-56
    PubMedGoogle Scholar
  • 11 Meyer J M. A rectrospective comparison of weight, lipid, and glucose changes between olanzapine- and risperidone-treated inpatients: metabolic outcomes after 1 year.  J Clin Psychiatry. 2002;  63 425-433
    PubMedGoogle Scholar
  • 12 Simpson G M, Glick I D, Weiden P J, Romano S J, Siu C O. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.  Am J Psychiatry. 2004;  161 1837-1847
    CrossrefPubMedGoogle Scholar
  • 13 Gupta S, Steinmeyer C, Frank B, Madhusoodanan S, Lockwood K, Lentz B, Keller P. Hyperglycemia and hypertriglyceridemia in real world patients on antipsychotic therapy.  Am J Ther. 2003;  10 348-355
    PubMedGoogle Scholar
  • 14 Wittchen H-U, Glaesmer H, März W, Stalla G, Lehnert H, Zeiher A M, Silber S, Koch U, Böhler S, Pittrow D, Ruf G. for the DETECT-Study Group . Cardiovascular risk factor in primarycare: methods and baseline prevalence rates - the DETECT program.  Curr Med Res Opin. 2005;  21 619-629
    CrossrefPubMedGoogle Scholar
  • 15 Laaser U. Nutzen und Kosten bei Früherkennung und Frühbehandlung der Hypercholesterinämie.  Z Kardiol. 1994;  83, Suppl 6 163-167
    PubMedGoogle Scholar
  • 16 Richter W O, Richter V, Rassoul F, Sonnichsen A C, Rotzsch W, Schwandt P. Kardiovaskuläre Risikofaktoren in den alten und neuen Bundesländern.  Fortschr Med. 1993;  111 214-218
    PubMedGoogle Scholar
  • 17 Spelsberg A, Weiland K, Stolpe S, Segerling M, Keil U. Bochumer Cholesterin und Blutdruckscreening-Studie 1990.  Fortschr Med. 1992;  110 387-392
    PubMedGoogle Scholar
  • 18 Assmann G, Schulte H. The importance of triglycerides: results from the Prospective Cardiovascular Munster (PROCAM) Study.  Eur J Epidemiol. 1992;  8, Suppl 1 99-103
    CrossrefPubMedGoogle Scholar
  • 19 Richter V, Rassoul F, Hentschel B, Kothe K, Krobara M, Unger R, Purschwitz K, Rotzsch W, Thiery J, Muradian K. Age-dependence of lipid parameters in the general population and vegetarians.  Z Gerontol Geriatr. 2004;  37 207-213
    PubMedGoogle Scholar
  • 20 Saari K, Koponen H, Laitinen J, Jokelainen J, Lauren L, Isohanni M, Lindeman S. Hyperlipidemia in persons using antipsychotic medication: a general population-based birth cohort study.  J Clin Psychiatry. 2004;  65 547-550
    PubMedGoogle Scholar
  • 21 Lund B C, Perry P J, Brooks J M, Arndt S. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach.  Arch Gen Psychiatry. 2001;  58 1172-1176
    PubMedGoogle Scholar
  • 22 Osser D N, Najarian D M, Dufresne R L. Olanzapine increases weight and serum triglyceride levels.  J Clin Psychiatry. 1999;  60 767-770
    PubMedGoogle Scholar
  • 23 Meyer J M. Novel antipsychotics and severe hyperlipidemia.  J Clin Psychopharmacol. 2001;  21 369-374
    CrossrefPubMedGoogle Scholar
  • 24 Henderson D C, Cagliero E, Gray C, Nasrallah R A, Hayden D L, Schoenfeld D A, Goff D C. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.  Am J Psychiatry. 2000;  157 975-981
    CrossrefPubMedGoogle Scholar
  • 25 Henderson D C, Nguyen D D, Copeland P M, Hayden D L, Borba C P, Louie P M, Freudenreich O, Evins A E, Cather C, Goff D C. Clozapine, Diabetes Mellitus, Hyperlipidemia, and Cardiovascular Risks and Mortality: Results of a 10-Year Naturalistic Study.  J Clin Psychiatry. 2000;  66 1116-1121
    PubMedGoogle Scholar
  • 26 International Diabetes Federation .The IDF consensus worldwide definition of the metabolic syndrome. 2005 www.idf.org
    Google Scholar
  • 27 Dilling H, Mombour W, Schmidt M H. Internationale Klassifikation psychischer Störungen. ICD-10 Kapitel V (F) Klinisch-diagnostische Leitlinien. 4. Aufl,. Bern; Huber 2000
    Google Scholar
  • 28 Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia.  Br J Psychiatry. 2000;  177 212-217
    CrossrefPubMedGoogle Scholar
  • 29 Joukamaa M, Heliovaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. Mental disorders and cause-specific mortality.  Br J Psychiatry. 2001;  179 498-502
    CrossrefPubMedGoogle Scholar
  • 30 Palmer B A, Pankratz V S, Bostwick J M. The lifetime risk of suicide in schizophrenia: a reexamination.  Arch Gen Psychiatry. 2005;  62 247-253
    PubMedGoogle Scholar
  • 31 Curkendall S M, Mo J, Glasser D B, Rose Stang M, Jones J K. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada.  J Clin Psychiatry. 2004;  65 715-720
    CrossrefPubMedGoogle Scholar
  • 32 Enger C, Weatherby L, Reynolds R F, Glasser D B, Walker A M. Serious cardiovascular events and mortality among patients with schizophrenia.  J Nerv Ment Dis. 2004;  192 19-27
    PubMedGoogle Scholar
  • 33 Casey D E, Haupt D W, Newcomer J W, Henderson D C, Sernyak M J, Davidson M, Lindenmayer J P, Manoukian S V, Banerji M A, Lebovitz H E, Hennekens C H. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia.  J Clin Psychiatry. 2004;  65, Suppl 7 4-18
    CrossrefPubMedGoogle Scholar
  • 34 Wetterling T. Hyperlipidämienebenwirkung bei Behandlung mit einem atypischen Neuroleptikum (Zotepin)?.  Psychiat Prax. 2002;  29 438-440
    PubMedGoogle Scholar
  • 35 Baymiller S P, McMahon R P, Buchanan R W. Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment.  Schizophr Res. 2003;  59 49-57
    CrossrefPubMedGoogle Scholar
  • 36 Consensus Development . Conference on Antipsychotic Drugs and Obesity and Diabetes.  J Clin Psychiatry. 2004;  65 265-272
    PubMedGoogle Scholar
  • 37 Marder S R, Essock S M, Miller A L, Buchanan R W, Casey D E, Davis J M, Kane J M, Lieberman J A, Schooler N R, Covell N, Stroup S, Weissman E M, Wirshing D A, Hall C S, Pogach L, Pi-Sunyer X, Bigger Jr J T, Friedman A, Kleinberg D, Yevich S J, Davis B, Shon S. Physical health monitoring of patients in schizophrenia.  Am J Psychiatry. 2004;  161 1334-1349
    CrossrefPubMedGoogle Scholar

Prof. Dr. Tilman Wetterling

Klinik für Psychiatrie und Psychotherapie, Vivantes Klinikum Hellersdorf

Myslowitzer Straße 45

12621 Berlin

Email: tilman.wetterling@vivantes.de

      >